Literature DB >> 26096687

Risks and Benefits of Bisphosphonate Therapies.

Carlen Reyes1, Mette Hitz2, Daniel Prieto-Alhambra1,3,4, Bo Abrahamsen5,6.   

Abstract

Bisphosphonates are the mainstay of osteoporosis treatment but also play a fundamental role in treating other bone diseases such as Osteogenesis Imperfecta, Pagets' disease, and in the prevention of adverse skeletal effects in certain cancers such as prostate cancer or multiple myeloma. In the last decades, the refinement of bisphosphonates and an increase in the number of new bisphosphonates commercialized has altered the clinical management of these diseases. Despite differences between randomized controlled trials and observational studies, overall all bisphosphonates licensed have proven to reduce the risk of fracture through the inhibition of bone resorption. Other beneficial effects include pain reduction in bone metastasis and potentially a decrease in mortality. However, the chronic nature of most of these disorders implies long-term treatments, which can be associated with long-term adverse effects. Some of the adverse effects identified include an increased risk of atypical femur fractures, osteonecrosis of the jaw, gastrointestinal side effects, or atrial fibrillation. The harm/benefit thinking and the constant update regarding these medications are vital in the day-to-day decision-making in clinical practices. The aims of this review are to compile the basic characteristics of these drugs and outline the most important benefits and side effects and provide a clinical context as well as a research agenda to fill the gaps in our knowledge.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BONE; OSTEOCLAST; OSTEOPOROSIS

Mesh:

Substances:

Year:  2016        PMID: 26096687     DOI: 10.1002/jcb.25266

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  35 in total

Review 1.  Coupling factors involved in preserving bone balance.

Authors:  Beom-Jun Kim; Jung-Min Koh
Journal:  Cell Mol Life Sci       Date:  2018-12-04       Impact factor: 9.261

Review 2.  Side effects of drugs for osteoporosis and metastatic bone disease.

Authors:  Michael Kriegbaum Skjødt; Morten Frost; Bo Abrahamsen
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

Review 3.  Bisphosphonates for advanced prostate cancer.

Authors:  Sascha Macherey; Ina Monsef; Franziska Jahn; Karin Jordan; Kwok Keung Yuen; Axel Heidenreich; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

4.  TRAP-positive osteoclast precursors mediate ROS/NO-dependent bactericidal activity via TLR4.

Authors:  Kazuaki Nishimura; Satoru Shindo; Alexandru Movila; Rayyan Kayal; Albassam Abdullah; Irma Josefina Savitri; Atsushi Ikeda; Tsuguno Yamaguchi; Mohammed Howait; Ayman Al-Dharrab; Abdulghani Mira; Xiaozhe Han; Toshihisa Kawai
Journal:  Free Radic Biol Med       Date:  2016-06-22       Impact factor: 7.376

5.  A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.

Authors:  Rachel K Surowiec; Lauren F Battle; Ferrous S Ward; Stephen H Schlecht; Basma M Khoury; Christopher Robbins; Edward M Wojtys; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2019-10-31       Impact factor: 4.398

6.  Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity.

Authors:  Jin-Young Lee; Da-Ae Kim; Eun-Young Kim; Eun-Ju Chang; So-Jeong Park; Beom-Jun Kim
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 7.  Metabolic Bone Diseases and New Drug Developments.

Authors:  Vijayakumar Natesan; Sung-Jin Kim
Journal:  Biomol Ther (Seoul)       Date:  2022-03-28       Impact factor: 4.231

8.  Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates.

Authors:  Yun Sun Lee; So Jeong Park; Jin Young Lee; Eunah Choi; Beom-Jun Kim
Journal:  Korean J Intern Med       Date:  2022-04-26       Impact factor: 3.165

Review 9.  Anabolic treatments for osteoporosis in postmenopausal women.

Authors:  Neelam Hassan; Celia L Gregson; Jon H Tobias
Journal:  Fac Rev       Date:  2021-05-05

Review 10.  Surgical Treatment for Bisphosphonate-related Atypical Femoral Fracture: A Systematic Review.

Authors:  Adel Ebrahimpour; Mehrdad Sadighi; Amir Human Hoveidaei; Mohammadreza Chehrassan; Reza Minaei; Hamed Vahedi; Sm Javad Mortazavi
Journal:  Arch Bone Jt Surg       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.